Key Highlights

  • ClearOne shares were up 78.01 percent to USD 6.07 in pre-market trading on November 2, 2026.
  • No company announcement for November 2, 2026 was identified in the research for this article.
  • The Cortigent Merger agreement was signed on July 1, 2026 and remained pending final regulatory approval as of October 30, 2026.
  • Vivani would own about 77.98 percent of the combined company after closing, excluding the financing.
  • The merger is conditioned on a financing of USD 10.0 million to USD 15.0 million.

What moved ClearOne in pre-market trading

ClearOne (NASDAQ:CLRO) was up 78.01 percent to USD 6.07 in pre-market trading on November 2, 2026. The implied prior close is about USD 3.41 (calculated).

No company announcement dated November 2, 2026 was identified. The most relevant recent item is a statement from Vivani Medical (NASDAQ:VANI), published October 30, 2026, that closing of its Cortigent merger with ClearOne remained pending final regulatory approval after an earlier expectation of an October close.

The pending Cortigent merger

Under the merger agreement announced July 2, 2026, Cortigent would become a Wholly Owned Subsidiary of ClearOne. A regulatory filing says Vivani would hold about 77.98 percent of the combined company, with 12,500,000 consideration shares out of about 16,030,412 total shares. Existing ClearOne holders would own about 16.69 percent.

Closing conditions include the financing, Nasdaq approval of the combined company's initial listing, and ClearOne net cash of at least USD 50,000 excluding financing proceeds. The filing says meeting the listing bid price requirement may necessitate a Reverse Stock Split but gives no ratio. The outside date is roughly late December 2026 (calculated from the filing terms).

Business background and recent updates

ClearOne historically made audio conferencing and collaboration products. It closed the sale of its Assets to Biamp Systems on October 24, 2025, covering intellectual property, product inventory and customer data, and said it would remain a public company. It also effected a 1-for-15 reverse stock split on June 9, 2025.

Cortigent is a clinical-stage, pre-revenue neurostimulation company formerly part of Second Sight Medical Products. Its Orion cortical visual prosthesis and stroke recovery system are investigational.

Risks to the story

The deal depends on a financing in units of one common share and one warrant, so new dilution is built into the structure. Closing also depends on regulatory approval, and the target is pre-revenue. Shares of a company in transition can swing sharply on thin liquidity, and the merger could be delayed or Fail to complete.

What to watch next

Key markers are any announcement of regulatory clearance, pricing of the financing, the Nasdaq listing decision and any reverse split ratio. The late December 2026 outside date frames the timeline.